Werth VP, Hejazi E, Pena SM, et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis. ACR 2017, abstract 7L.
ACR 2018
okt 2018
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE